United States

STAAR Surgical Co (STAA.OQ)

STAA.OQ on NASDAQ Stock Exchange Global Market

4:00pm EDT
Change (% chg)

$0.10 (+1.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for STAA.OQ


STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in... (more)


Beta: 1.29
Market Cap(Mil.): $411.37
Shares Outstanding(Mil.): 40.93
Dividend: --
Yield (%): --


  STAA.OQ Industry Sector
P/E (TTM): -- 32.10 15.85
EPS (TTM): -0.16 -- --
ROI: -14.38 13.54 -8.31
ROE: -16.71 15.90 -7.95

Staar Surgical to pay $7 million in investor suit over FDA violations

Staar Surgical Co, a manufacturer of implantable lenses to correct vision problems, has agreed to pay $7 million to resolve a lawsuit claiming the company misled investors about its compliance with Food and Drug Administration regulations.

Jun 21 2017

BRIEF-Staar Surgical files for potential mixed shelf offering

* Staar Surgical Co files for potential mixed shelf offering of up to $200 million - SEC filing

May 11 2017

BRIEF-STAAR Surgical announces CE Mark approval for the EVO+ visian ICL with aspheric (EDOF) optic

* STAAR Surgical announces CE Mark approval for the EVO+ Visian ICL with aspheric (EDOF) optic

May 11 2017

BRIEF-Staar Surgical reports Q1 sales $20.4 million

* Q1 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S

May 03 2017

BRIEF-Staar Surgical names Deborah Andrews interim CFO

* Steve Brown has resigned his position as chief financial officer effective April 28, 2017 Source text for Eikon: Further company coverage:

Apr 05 2017

BRIEF-Stephen Brown notifies intention to resign as chief financial officer of STAAR Surgical

* Stephen Brown notified co of his intention to resign as vice president and chief financial officer

Apr 04 2017

BRIEF-Staar Surgical Q4 adjusted earnings per share $0.02

* Staar Surgical Co - on-going FDA remediation effort finished quarter on-track and on-budget

Mar 02 2017

Earnings vs. Estimates